Contact Greg King
Fibralign’s first product BioBridge is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120M people and has no cure (World Health Org, other sources). The Company successfully completed a large animal study with Stanford (DoD funded) that validated BioBridge treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study with Stanford. Fibralign has a strong IP position (11 patents, 14 pending) and a scalable manufacturing process for making this and other devices.